PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 405/06, A61K 31/495, 31/34 — A1

(11) International Publication Number: **WO 98/54178**

(43) International Publication Date: 3 December 1998 (03.12.98)

(21) International Application Number: PCT/US98/10633

(22) International Filing Date: 26 May 1998 (26.05.98)

(30) Priority Data:

60/047,950	29 May 1997 (29.05.97)	US
9714320.0	7 July 1997 (07.07.97)	GB

(71) Applicant *(for all designated States except US)*: MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: ASKIN, David [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). HOERRNER, R., Scott [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). PURICK, Robert, M. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). REIDER, Paul [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). VARSOLONA, Richard, J. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). VOLANTE, Ralph, P. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: SULFATE SALT OF AN HIV PROTEASE INHIBITOR HAVING AN IMPROVED ORAL ABSORPTION AND BIOAVAILABILITY



H_2SO_4 (A)

(57) Abstract

This invention relates to a sulfate salt of an HIV protease inhibitor, Compound (A), which is useful in the treatment of AIDS, ARC or HIV infection in adults and children. More specifically, the invention provides a sulfate salt of the HIV protease inhibitor, Compound (A) having substantially improved solibility in dilute HCl (gastric acid) solution which results in much greater oral absorption and bioavailability in animal models. Processes for making the sulfate salt of the particular HIV protease inhibitor compounds are also disclosed.